Live Breaking News & Updates on தலைமை வணிகரீதியானது அதிகாரி மர்டு கோர்டந்

3 Min Read
(Reuters) - U.S. biotech Amgen Inc on Tuesday provided a 2021 earnings forecast below Wall Street estimates and said it had paused or halted enrollment for clinical trials of three cancer drugs.
Slideshow ( 2 images )
The company also said it expects net selling prices for its drugs to fall by a rate in the mid-single digits this year - after a drop of 6% in 2020 - and the COVID pandemic will continue to impact sales.
Amgen shares, which closed at $240.49, were down $4.37, or 2%, at $236.12 after hours.
For 2021, Amgen forecast adjusted earnings of $16.00 to $17.00 per share, putting the midpoint below analysts’ estimates of $17.03 per share, according to IBES data from Refinitiv. The full-year revenue forecast of $25.8 billion to $26.6 billion was more in line with analyst projections of $26.45 billion. ....

Berkrot Shri Navaratnam , Michael Yee , Deena Beasley , Murdo Gordon , Thomson Reuters Trust Principles , Amgen Inc On , Amgen Inc , Wall Street , Chief Commercial Officer Murdo Gordon , Bill Berkrot , Thomson Reuters Trust , Company News , Generic Pharmaceuticals Trbc Level 5 , Biotechnology Amp Medical Research Trbc Level 4 , Pharmaceuticals Nec Trbc Level 5 , Pharmaceuticals Amp Medical Research Trbc Level 2 , Performance Results Earnings , Results Forecasts Warnings , Reuters Top News , United States , மைக்கேல் யீ , தீனா பீஸ்லி , மர்டு கோர்டந் , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ப்ரிந்ஸிபல்ஸ் , மகேன் இன்க் ஆன் , மகேன் இன்க் ,